Napredna pretraga

Pregled bibliografske jedinice broj: 710792

Fatal outcome of posterior “reversible” encephalopathy syndrome in metastatic colorectal carcinoma after irinotecan and fluoropyrimidine chemotherapy regimen : case report


Dedić Plavetić, Natalija; Rakušić, Zoran; Ozretić, David; Simetić, Luka; Mišir Krpan, Ana; Bišof, Vesna
Fatal outcome of posterior “reversible” encephalopathy syndrome in metastatic colorectal carcinoma after irinotecan and fluoropyrimidine chemotherapy regimen : case report // World journal of surgical oncology, 12 (2014), 264-1 doi:10.1186/1477-7819-12-264 (međunarodna recenzija, članak, znanstveni)


Naslov
Fatal outcome of posterior “reversible” encephalopathy syndrome in metastatic colorectal carcinoma after irinotecan and fluoropyrimidine chemotherapy regimen : case report

Autori
Dedić Plavetić, Natalija ; Rakušić, Zoran ; Ozretić, David ; Simetić, Luka ; Mišir Krpan, Ana ; Bišof, Vesna

Izvornik
World journal of surgical oncology (1477-7819) 12 (2014); 264-1

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Chemotherapy; fluoropyrimidine; fluorouracil; irinotecan; posterior reversible encephalopathy syndrome

Sažetak
Posterior reversible encephalopathy syndrome (PRES) is a clinicoradiologic entity characterized by headaches, altered mental status, seizures, and visual disturbances. It can occur in many different clinical entities such as severe hypertension and pre-eclampsia, or due to cytotoxic or immunosuppressive therapies. The pathogenesis of PRES is unclear, with dysregulated cerebral auto-regulation and endothelial dysfunction as important mechanisms proposed. Endothelial dysfunction is important especially in cases associated with cytotoxic therapies. Herein, we describe a patient with PRES with fatal outcome, who presented 5 days after the infusion of cycle 1 of irinotecan hydrochloride, leucovorin calcium, and fluorouracil (FOLFIRI) regimen chemotherapy, without prior hypertension and other comorbidity, suggesting a link between PRES and FOLFIRI regimen. To our knowledge, this case report is the first describing PRES after FOLFIRI regimen, although others have described PRES after FOLFIRI with bevacizumab in colonic cancer patients.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Ustanove
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati